SOPHiA DDM™ Platform › Measurable Residual Disease (MRD)
SOPHiA DDM™ for Measurable Residual Disease
Go beyond complete response with targeted NGS MRD analysis
Identify even the smallest traces of cancer cells by combining the power of next-generation sequencing (NGS) and the advanced analytical capabilities of the SOPHiA DDM™ Platform.
Overview
Confidently detect the last cancer cells
More than 50% of Acute Myeloid Leukemia (AML) patients relapse within three years after achieving complete remission.1 The SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution utilizes targeted NGS analysis to accurately detect variants down to 0.01% variant allele frequency (VAF) for key genes linked to AML.
Get the complete MRD story
Simultaneously assess 23 ELN guideline-recommended genes to identify and monitor AML-associated mutations in a single sample.
The SOPHiA DDM™ RAM Solution utilizes a decentralized, platform-agnostic workflow powered by advanced analytics, enabling clinical research in MRD and accelerating breakthrough discoveries.
1. www.leukameiacare.org.uk
Key Features
Aim for the right targets in MRD detection
Empower robust decision-making with accurate detection of key AML genomic biomarkers, streamlined variant interpretation, and simplified longitudinal monitoring.
Increase sensitivity
Leverage our proprietary CUMIN™ molecular adaptor technology for ultrasensitive variant detection with a limit of detection (LoD) down to 0.01% VAF.
Boost efficiency
Enhance productivity with NextSeq® and NovaSeq™ compatibility, and automated workflows on leading liquid handling robots.
Analyze tumor evolution
Utilize a dedicated interface for longitudinal variant monitoring to visualize the mutational landscape and its evolution over time.
Workflow
See what other tests might miss with NGS
Streamline your sample-to-report MRD workflow with solutions designed to enhance genomic profiling and monitoring of residual disease.
Flexible and scalable library preparation
Use one universal, automatable protocol for sequencing on NextSeq and NovaSeq systems.
Advanced analytical performance
Rely on multiple MRD markers to increase the gap between the signal and the noise.
Longitudinal monitoring
Leverage a user-friendly interface that simplifies tracking of AML dynamics over time.
Streamlined variant interpretation
Quickly assess variants with enhanced tertiary analysis and community-driven insights.
Analytics
Enhance your MRD analysis
Expand your MRD detection capabilities with the power of NGS and the advanced analytics of the SOPHiA DDM™ Platform.
SOPHiA DDM™ enables sensitive detection of MRD markers at allele frequencies as low as 0.01% with excellent sensitivity. By incorporating our proprietary CUMIN™ unique molecular identifier (UMI) technology into sample preparation and leveraging our bioinformatic expertise, errors introduced during library preparation, target enrichment, or sequencing can be filtered out and true variant alleles identified. Moreover, precise molecule counting allows you to reliably measure the MRD signal.
Our sophisticated SNV and Indel calling algorithm implements relevant analytical modules that are tailored to reduce noise linked to sample type, sequencer, and library preparation. Owing to probabilistic, molecule-based signal estimation, molecular signal and noise measurements for each individual MRD marker are provided.
MRD Score provides a measure of the MRD signal reliability by comparing the signal of one or more selected MRD markers to the expected noise levels at the genomic position of each marker. A score of 50 or more, on a scale of 0-100, means that the signal is significantly higher than the expected background noise.
Unlock MRD insights over time
SOPHiA DDM™ with its dedicated OncoPortal™ Mutation Tracker add-on streamlines longitudinal comparisons by consolidating various SOPHiA DDM™ RAM Solution time-point results into a single analysis. This add-on module enables to track changes in variants and adapt thresholds to discern variant presence or absence.
SOPHiA DDM™ RAM Solution
Stay ahead of the curve with continuous MRD monitoring
“This longitudinal interface represents the solution we’ve been seeking to unite our oncologists in embracing broader adoption of NGS It’s the missing piece that unlocks new frontiers in personalized, data-driven medicine.”
Dr. Christophe Marzac
Head of the Hematology Gustave Roussy Institute
Resources
Featured Resources
SOPHiA DDM™ RAM Solution
Aim for the right targets in measurable residual disease detection